logo-loader
viewGenprex, Inc.

Genprex issues development updates for lung-cancer drug Oncoprex

A study examined the effects of the tumor suppressor gene TUSC2 found in Oncoprex in combination with immunotherapy treatment

Diagram of lungs
Genprex is a clinical stage gene therapy company based in Austin, Texas focused on developing cancer treatments

Genprex Inc (NASDAQ:GNPX) announced an update Monday on the development of its non-small cell lung cancer drug, including positive study results.

In April, a study of its lead drug Oncoprex at the University of Texas was completed. The study examined the effects of the tumor suppressor gene TUSC2 found in Oncoprex in combination with immunotherapy treatment.

The study was part of a sponsored research agreement between the company and the UT MD Anderson Cancer Center, and research is still ongoing. Researchers are also looking into TUSC2 used in concert with small molecule drugs and immunostimulatory adjuvants, which activate the body’s immune system.

READ: Genprex retains pharma branding agency to select a name for its lead drug

“Recent studies have shown that less than half of cancer patients qualify for approved immunotherapies based on the patient’s PD-1 or PD-L1 protein expression level,” Chief Operating Officer Julien Pham said. “Current immunotherapy treatment is only benefitting a small number of cancer patients. We are working to fill this gap by combining our lead drug candidate with approved immunotherapies to give patients more treatment options.”

Genprex is a clinical stage gene therapy company based in Austin, Texas focused on developing cancer treatments.

Its stock slipped 3.2% to $1.20 a share in morning trading. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Genprex, Inc.

Price: 0.34 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $5.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex's active drug ingredient validated by independent...

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher. Varner notes the study was published in the...

on 09/20/2019

2 min read